October, 2025
October 2025
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  
Michael Makris on Biomarin’s Decision to Divest Roctavian
Oct 30, 2025, 03:53

Michael Makris on Biomarin’s Decision to Divest Roctavian

Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, Editor-in-Chief of RPTH Journal, shared on LinkedIn:

”Important.

Biomarin, the only manufacturer of an approved hemophilia A gene therapy has decided to divest Roctavian and remove it from their portfolio.

They plan to sell it on to a more established hemophilia company, if they can find a buyer.

The problems have been the high cost and limited durability.

This is a sad turn of events but not surprising to anybody who follows the field.

We suspected that sales were poor, but not this poor, as indicated in their press release.

This is their press release.”

Michael Makris on Biomarin's Decision to Divest Roctavian

Stay updated with Hemostasis Today.